Literature DB >> 8790218

Quantitative imaging of iodine-124 with PET.

K S Pentlow1, M C Graham, R M Lambrecht, F Daghighian, S L Bacharach, B Bendriem, R D Finn, K Jordan, H Kalaigian, J S Karp, W R Robeson, S M Larson.   

Abstract

UNLABELLED: PET is potentially very useful for the accurate in vivo quantitation of time-varying biological distributions of radiolabeled antibodies over several days. The short half-lives of most commonly used positron-emitting nuclides make them unsuitable for this purpose. Iodine-124 is a positron emitter with a half-life of 4.2 days and appropriate chemical properties. It has not been widely used because of a complex decay scheme including several high energy gamma rays. However, measurements made under realistic conditions on several different PET scanners have shown that satisfactory imaging and quantitation can be achieved.
METHODS: Whole-body and head-optimized scanners with different detectors (discrete BGO, block BGO and BaF2 time-of-flight), different septa and different correction schemes were used. Measurements of resolution, quantitative linearity and the ability to quantitatively image spheres of different sizes and activities in different background activities were made using phantoms.
RESULTS: Compared with conventional PET nuclides, resolution and quantitation were only slightly degraded. Sphere detectability was also only slightly worse if imaging time was increased to compensate for the lower positron abundance.
CONCLUSION: Quantitative imaging with 124I appears to be possible under realistic conditions with various PET scanners.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790218

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  57 in total

1.  124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

Authors:  Joseph A O'Donoghue; Peter M Smith-Jones; John L Humm; Shutian Ruan; Daniel A Pryma; Achim A Jungbluth; Chaitanya R Divgi; Jorge A Carrasquillo; Neeta Pandit-Taskar; Yuman Fong; Vivian E Strong; Nancy E Kemeny; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-11-08       Impact factor: 10.057

2.  Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging.

Authors:  H Herzog; S M Qaim; L Tellmann; S Spellerberg; D Kruecker; H H Coenen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-15       Impact factor: 9.236

Review 3.  Immuno-positron emission tomography in cancer models.

Authors:  Smitha Reddy; Matthew K Robinson
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

4.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

5.  Is PET always an advantage versus planar and SPECT imaging?

Authors:  Giuliano Mariani; Laura Bruselli; Adriano Duatti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 6.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 7.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 8.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

Review 9.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

10.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Authors:  Gobalakrishnan Sundaresan; Paul J Yazaki; John E Shively; Ronald D Finn; Steven M Larson; Andrew A Raubitschek; Lawrence E Williams; Arion F Chatziioannou; Sanjiv S Gambhir; Anna M Wu
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.